A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Trial Profile

A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2017

At a glance

  • Drugs Docetaxel (Primary) ; Sorafenib (Primary) ; Cisplatin
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Nasopharyngeal cancer; Oropharyngeal cancer; Salivary gland cancer; Squamous cell cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Dec 2017.
    • 27 Jul 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2016.
    • 13 Apr 2015 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top